Clinical Studies & Research at Friendship Hospital for Animals
Currently Enrolling – STEM CELL TREATMENT STUDY FOR CATS WITH CHRONIC KIDNEY DISEASE (View PDF)
TRIAL ELIGIBILITY
We are enrolling cats that meet the following criteria:
- Feline patients diagnosed with chronic kidney disease (CKD), IRIS grade 2 or greater prior to enrollment.
- Cats should not have cancer or other concurrent disease conditions that are not controlled/stable.
- Cats should not have received a stem cell product in the past.
REQUIREMENTS
The stem cell therapy consists of an initial treatment followed by a second treatment 14 days apart.
FULLY FUNDED STUDY BENEFITS
- Your client’s cat will receive specialty veterinary care throughout the study, including physical exams, blood work, and urinalysis at NO OUT-OF-POCKET cost to the pet parent.
- There is a 67% chance that the cats will receive drug. 33% of cats will receive a placebo treatment.
We would be happy to provide you with additional information regarding the study. Please reach out to our Clinical Trials Coordinator, Noa Zeevi at 202-363-7300 or clinicaltrials@friendshiphospital.com
Currently Enrolling – Collagen Study
*We are evaluating a treatment for urinary incontinence that is novel in dogs.
*The product has been used for incontinence in women and is also administered in the joints of dogs and horses to be used to help with joint lameness.
*This is a minimally invasive treatment for urinary incontinence in dogs. Compared to urethral collagen bulking, a procedure performed for decades to manage urinary incontinence, we hope that this product produces a prolonged response.
*Patient benefits: potentially one-time procedure vs. collagen administration that needs to be repeated as needed (typically yearly).
*Clients responsibility: Cover procedure costs only – the bulking agent is administered at no charge.
*Financial benefits: $1,000 savings compared to cost of collagen injection.
*Follow-up: 1 & 3 month phone call or email with update. Recheck as needed.
We would be happy to provide you with additional information regarding the study. Please reach out to our Clinical Trials Coordinator, Noa Zeevi at 202-363-7300 or clinicaltrials@friendshiphospital.com
Currently Enrolling – The Halt Study (View PDF)
Study Summary
This is a multi-site, blinded, randomized, placebo-controlled clinical field study to provide substantial evidence of effectiveness of a disease modifying drug intervention in the management of ventricular hypertrophy in cats with subclinical HCM. The study will be conducted at multiple clinical sites that are experienced in treating cats with HCM. The study will consist of up to a 14-day screening period, followed by a 12-month once-weekly dosing period, with five post-enrollment study visits.
Inclusion/Exclusion Criteria
A non-exhaustive list of the clinically relevant study inclusion and exclusion enrollment criteria are detailed below.
Inclusion Criteria
- Echocardiographic diagnosis of ACVIM Stage B1 or B2 HCM
- Male or surgically spayed female cat
- Body weight ≥2.5kg
- Age ≥18 months and <15 years at enrollment
- Reference laboratory confirmed NTproBNP >100 pmol/L at screening visit
- ACVIM Stage B2 cats should be receiving clopidogrel 18.75 mg prior to or from screening visit
Exclusion Criteria
- Cats with advanced or symptomatic HCM (ACVIM Stage C/D) at Screening or at any point in medical history
- Sexually intact female
- Cats unable to take and/or owners unable to administer oral medications
- Any echocardiographic diagnosis that is not associated with HCM
- Other significant systemic or congenital illness (e.g Diabetes Mellitus, IRIS stage 2 or greater CKD, hepatic disease, hyperthyroidism)
- Subjects requiring urgent treatment Active Infections
- Non-Healed Wounds
- Treatment with prohibited medications (e.g angiotensin receptor blockers, beta blockers, ace inhibitors, diuretics, calcium channel blockers, chronic use corticosteroids) and inability to undergo washout for at least 14 days prior to screening.
Study participation incentives
- Opportunity for your client to access a novel disease modifying treatment.
- Client access to board certified cardiologist care the duration of the study.
- Free of charge diagnostics required per the study protocol.
- Client compensation of $500 on completion of the study.
If you are interested in study participation or you have a client that you would like to refer, please contact our Cardiology department at cardiology@friendshiphospital.com
